Foley Partner David Rosen was quoted in an article that appeared in FDA Week on June 24, 2010 titled “OIG, Stakeholders Urge FDA To Clamp Down On Foreign Clinical Trials.” Rosen discusses criticisms directed towards the Food and Drug Administration (FDA) by lawmakers and drug safety advocates for what they view as lackluster oversight of clinical trials conducted abroad. He states that data collected during pivotal trials is likely to come under scrutiny by the FDA, adding that the majority of companies are working hard to ensure that data generated outside the U.S. is of very high quality.
People
Related News
April 13, 2026
In the News
Increase in Demand and Firm Growth Led Foley to Large Leaps in Revenue and PEP in a 'Year When It All Came Together'
Foley & Lardner LLP saw double-digit increases and all-time highs across all financial metrics in 2025 as noted in The American Lawyer article, “Foley Grows Revenue by Nearly 14%, PEP by 27%, in a 'Year When It All Came Together'.”
April 10, 2026
In the News
Foley's Texas Media Roundtable Highlighted for Insights on Today's Energy Transformations
Foley & Lardner LLP is featured across media for the firm’s recent roundtable discussion on energy trends related to grid reliability, data centers, and capital investments.
April 10, 2026
In the News
Deanna Reitman and Glenn Reitman Highlighted Across Media for Foley Arrival
Foley & Lardner LLP partners Deanna Reitman and Glenn Reitman attracted widespread media coverage for their recent arrival to the firm’s Houston office.